Cargando…
How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?
Assessment of measurable residual disease, also called “minimal residual disease,” in patients with acute myeloid leukemia in morphological remission provides powerful prognostic information and complements pretreatment factors such as cytogenetics and genomic alterations. Based on data that low lev...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Ferrata Storti Foundation
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669140/ https://www.ncbi.nlm.nih.gov/pubmed/31273094 http://dx.doi.org/10.3324/haematol.2018.208454 |